GCP
ACER

GSA Capital Partners’s Acer Therapeutics Inc ACER Stock Holding History

GSA Capital Partners’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-82,421
Closed -$237K – 1696
2020
Q3 		$237K Buy
+82,421
New +$266K 0.04% 902

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return

GSA Capital Partners's ACER Position: Q4 2020 in Review

GSA Capital Partners sold out of Acer Therapeutics Inc (ACER) in Q4 2020, closing a stake of 82,421 shares — an estimated $237K sold.

GSA Capital Partners first reported a position in ACER in Q3 2020 and held it in 1 quarter. The position peaked at $237K in Q3 2020. 30 funds tracked by Wall St. Rank hold ACER as of Q4 2020.

  • GSA Capital Partners reported no remaining Acer Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • GSA Capital Partners sold 82,421 Acer Therapeutics Inc shares in Q4 2020, an estimated $237K.
  • GSA Capital Partners first reported a position in Acer Therapeutics Inc in Q3 2020 and held it in 1 quarter.
  • GSA Capital Partners's Acer Therapeutics Inc position peaked at $237K in Q3 2020.
  • 30 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2020.

Based on GSA Capital Partners's 13F filing for Q4 2020, filed 3 Feb 2021.